Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) was the target of a large decline in short interest in June. As of June 30th, there was short interest totalling 228,602 shares, a decline of 60.4% from the June 15th total of 577,279 shares. Based on an average daily volume of 155,602 shares, the days-to-cover ratio is presently 1.5 days. Approximately 2.2% of the company’s stock are sold short.

In other Cellular Biomedicine Group news, CEO Tony Liu purchased 10,000 shares of Cellular Biomedicine Group stock in a transaction dated Tuesday, June 6th. The stock was acquired at an average price of $6.83 per share, for a total transaction of $68,300.00. Following the acquisition, the chief executive officer now owns 119,825 shares in the company, valued at approximately $818,404.75. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 8.20% of the company’s stock.

Separately, Maxim Group restated a “buy” rating and set a $18.00 price target on shares of Cellular Biomedicine Group in a research note on Monday, April 10th.

Shares of Cellular Biomedicine Group (NASDAQ:CBMG) opened at 8.60 on Friday. Cellular Biomedicine Group has a 12-month low of $5.05 and a 12-month high of $15.68. The stock’s market capitalization is $122.89 million. The stock has a 50 day moving average of $7.23 and a 200 day moving average of $10.77.

COPYRIGHT VIOLATION WARNING: “Cellular Biomedicine Group, Inc. (CBMG) Short Interest Down 60.4% in June” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/07/16/cellular-biomedicine-group-inc-cbmg-short-interest-down-60-4-in-june.html.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.

Receive News & Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.